Recently, Anlong Biotechnology and Sunshine Novo jointly announced that the clinical trial application for the innovative hypertension drug ABA001, jointly developed by the two parties, has been officially accepted by the Drug Evaluation Center of the National Medical Products Administration (acceptance number: CXHL2600091). This marks a new breakthrough in China's long-term treatment of hypertension.
ABA001 is a GalINAc siRNA drug targeting angiotensinogen, belonging to Class I innovative drugs. This drug aims to use cutting-edge RNA interference technology to provide a revolutionary treatment plan for hypertensive patients worldwide that can achieve long-term stable blood pressure reduction with a safe and effective single injection.
The global clinical trials of the target drug Zilebesiran have fully validated the effectiveness and safety of this mechanism.
The data shows that a single dose can achieve sustained and stable antihypertensive efficacy for up to 24 weeks, and is expected to benefit cardiovascular risk patients, providing solid scientific evidence for the development of ABA001. Non clinical studies on ABA001 have shown that a 1mpk dose of this product can significantly reduce blood pressure, with good animal tolerance and high safety. It is expected to achieve a lower dosage and longer lasting antihypertensive effect. Its long-acting administration characteristics are expected to break through existing treatment bottlenecks and provide better treatment options for hypertensive patients.
Ruibo Biotech's siRNA drug RBD5044 targeting ApoC3 has obtained implied approval for phase I clinical trials in China
On January 23, 2026, Suzhou Ruibo Biotechnology Co., Ltd. (Ruibo Biotechnology, Hong Kong Stock Exchange code: 06938) announced that its independently developed siRNA drug RBD5044 targeting ApoC3 had obtained implied approval for Phase I clinical trials from the National Medical Products Administration (NMPA) on January 22, 2026.
RBD5044 is a small nucleic acid drug developed based on RiboGalSTARTM liver targeting technology platform for the treatment of hypertriglyceridemia. It is also the second siRNA targeting ApoC3 to enter clinical development worldwide.
The current Phase I clinical trial results show that a single administration can achieve significant inhibition of apolipoprotein C3 (ApoC3) up to 84%, accompanied by a 70% decrease in triglyceride (TG) levels. During the 6-month follow-up, the TG levels of the subjects remained stable below the baseline value of 50%, and their blood lipids were comprehensively improved. At the same time, RBD5044 also showed good tolerability, and no dose dependent adverse reactions or elevated liver enzymes were observed at the highest dose. Clinical data on safety and efficacy show that RBD5044 has the potential to become the best in class therapy.
The fourth indication for GLP-1 in Zhongsheng Pharmaceutical has been approved for clinical use
On January 23, 2026, the CDE official website announced that the RAY1225 injection from Zhongsheng Pharmaceutical was approved for clinical use in the treatment of obesity combined with obstructive sleep apnea (OSA). This is the fourth approved clinical indication of the product, and the others are obesity, type 2 diabetes and fatty hepatitis related to metabolic dysfunction. RAV1225 is an innovative structural peptide drug developed by Zhongsheng Ruichuang with global independent intellectual property rights.
It has dual activation activity of GLP-1 receptor and GIP receptor, and can promote insulin secretion and inhibit glucagon in a glucose dependent manner to control blood sugar. At the same time, it can inhibit gastric emptying, suppress appetite, reduce weight, lower peripheral insulin resistance, improve liver steatosis and ballooning. Thanks to its excellent pharmacokinetic properties, RAY1225 has the potential for ultra long acting drugs to be injected every two weeks.
Jixing Pharmaceutical has completed a $287 million D1 round of financing to advance the development of oral GLP-1 and cardiac metabolic pipelines
Recently, Jixing Pharmaceutical Co., Ltd. (hereinafter referred to as "Jixing"), a clinical stage biopharmaceutical company dedicated to developing innovative therapies for cardiovascular metabolic disease patients worldwide, announced today that it has successfully completed its D1 round of financing, raising up to 287 million US dollars. The funds raised in this round of financing will mainly be used to promote the development of the pipeline CX11 under research. CX11 is an orally administered small molecule GLP-1 RA with unique advantages.
Currently, Jixing is conducting a phase 2 clinical trial in the United States to treat obese and overweight patients, and its partner Wentai Pharmaceutical is conducting a phase 3 clinical trial in China. In addition, the raised funds will also be used to promote other cardiovascular metabolism projects, including pipeline development for acute ischemic stroke and hypertension.
This round of investors SR One, TCGX, Adage Capital Management, RA Capital Management, HBM Healthcare Investments, SymBiosis.Adage Capital Management,Inwus,SilverArc Capital And other investors. Existing investors RTW Investments and Dian Capital continue to participate, demonstrating their continued confidence in CX11's unique clinical advantages, Jixing's clinical development capabilities, and the company's long-term strategy.
